Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | SDHB | P21912 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21817221 | 0.84 | WDR5 (0.41) | CFTRWDR5KDM4EDHODHMAP2K1 | |
| SCHEMBL30645890 | 0.81 | TDP2 (0.41) | CFTRKDM4EDHODHTDP2POLB | |
| SCHEMBL26605018 | 0.81 | TDP2 (0.41) | CFTRKDM4EDHODHTDP2POLB | |
| SCHEMBL844529 | 0.76 | KDM4E (0.51) | CFTRKDM4EMAP2K1TDP1HDAC6 | |
| SCHEMBL21817305 | 0.76 | WDR5 (0.64) | WDR5 | |
| SCHEMBL21817786 | 0.74 | CFTR (0.43) | CFTRWDR5CYP46A1SLC6A4SLC6A3 | |
| SCHEMBL19583620 | 0.72 | PSMD14 (0.44) | CFTRKDM4ESOS1MRGPRX4 | |
| SCHEMBL21201095 | 0.69 | PSMD14 (0.44) | CFTRKDM4EMAP2K1 | |
| SCHEMBL973413 | 0.69 | ALOX15 (0.45) | CFTRKDM4EMAP2K1SDHBTDP1 | |
| SCHEMBL2148915 | 0.68 | KDM4E (0.43) | CFTRKDM4EDHODHMAP2K1TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844044-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | CFTR 2542/4885WDR5 1/4885KDM4E 121/4885 |
| US-10844044-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | CFTR 2444/4885WDR5 1/4885KDM4E 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.